Market Value: BrainStorm Cell Therapeutics Inc. (BCLI)

The Brainstorm Cell (BCLI) price chart demonstrates the dynamics of a company whose barriers to entry are driven by colossal R&D investments and strict FDA oversight. The business positions itself as a pioneer in regenerative medicine, having earned recognition from patient communities for its innovative approach to treating ALS. Meanwhile, the pricing policy is currently at the level of 0.01, as the commercial implementation of drugs is only possible after obtaining all necessary approvals.

BrainStorm Cell Therapeutics - BCLI Market Capitalization (period 07/04/2022 - 08/02/2025)

BCLI (BrainStorm Cell Therapeutics Inc.): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price BrainStorm Cell Therapeutics|BCLI - Consensus Target

- company stock exchange capitalization indicators:

Market Value BrainStorm Cell Therapeutics Inc.|BCLI - Total Company Value

- book value of equity indicators:

Book Value per Share BrainStorm Cell Therapeutics|BCLI - Book Valuation of Business|Market Value to Book Value Ratio brainstorm-cell.com|BCLI - Total Business Assets

- business debt structure and liquidity details:

Total Debt to Capital Brainstorm Cell|BCLI - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Brainstorm Cell|BCLI - Company Aggregate Debts|Debt to Book Capitalization Ratio BrainStorm Cell Therapeutics Inc.|BCLI - Company Long-Term Loans and Borrowings|Company Short-Term Debt BrainStorm Cell Therapeutics|Quick Ratio brainstorm-cell.com

- financial results and valuation multiples details:

BCLI - Company Net Income|Expected Profit Brainstorm Cell|BCLI - Company Value to Net Income|Forward P/E Multiple Brainstorm Cell Therapeutics, Inc.|BCLI - PEG Multiple|EV/EBITDA Multiple BrainStorm Cell Therapeutics Inc.|BCLI - Operating income before deduction of amortization|Earnings per share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months brainstorm-cell.com|BCLI - Expected net earnings per share growth this year|Expected earnings per share growth for next year Brainstorm Cell

Fundamental company analysis:BCLI (BrainStorm Cell Therapeutics)

Brainstorm Cell (BCLI) is developing high-tech cell therapy methods amidst unstable global supply chains. Market capitalization reflects the aggregate value of all shares, determining the business's market weight. By analyzing the company's capitalization volumes, an investor sees the result of multiplying the current price by the number of securities. This calculation requires adjustment for splits to eliminate technical distortions. The indicator's dynamics demonstrate capital resilience to geopolitical risks and patent disputes.

Key competitors